These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 32406492)
1. Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial. Angiolillo DJ; Baber U; Mehran R Cardiovasc Res; 2020 Jun; 116(7):e70-e72. PubMed ID: 32406492 [No Abstract] [Full Text] [Related]
2. Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials. Zhang Z; Chen O J Cardiovasc Pharmacol; 2021 May; 77(5):536-543. PubMed ID: 33760801 [TBL] [Abstract][Full Text] [Related]
3. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention. Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798 [TBL] [Abstract][Full Text] [Related]
4. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Gao C; Tomaniak M; Takahashi K; Kawashima H; Wang R; Hara H; Ono M; Montalescot G; Garg S; Haude M; Slagboom T; Vranckx P; Valgimigli M; Windecker S; van Geuns RJ; Hamm C; Steg PG; Onuma Y; Angiolillo DJ; Serruys PW Cardiovasc Diabetol; 2020 Oct; 19(1):179. PubMed ID: 33066794 [TBL] [Abstract][Full Text] [Related]
5. Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials. Verdoia M; Savonitto S; Dudek D; Kedhi E; De Luca G Vascul Pharmacol; 2021 Apr; 137():106828. PubMed ID: 33385541 [TBL] [Abstract][Full Text] [Related]
6. ISAR-REACT 5 - What have we learned? Kubica J; Jaguszewski M Cardiol J; 2019; 26(5):427-428. PubMed ID: 31536136 [No Abstract] [Full Text] [Related]
7. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. Serruys PW; Takahashi K; Chichareon P; Kogame N; Tomaniak M; Modolo R; Chang CC; Komiyama H; Soliman O; Wykrzykowska JJ; de Winter RJ; Ferrario M; Dominici M; Buszman P; Bolognese L; Tumscitz C; Benit E; Stoll HP; Hamm C; Steg PG; Onuma Y; Jüni P; Windecker S; Vranckx P; Colombo A; Valgimigli M Eur Heart J; 2019 Aug; 40(31):2595-2604. PubMed ID: 31397487 [TBL] [Abstract][Full Text] [Related]
8. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963 [TBL] [Abstract][Full Text] [Related]
9. Prasugrel vs. ticagrelor after acute coronary syndrome: a critical appraisal of the ISAR-REACT 5 trial. Sulzgruber P; Niessner A Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):273-274. PubMed ID: 31865384 [No Abstract] [Full Text] [Related]
10. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Cannon CP; Gropper S; Bhatt DL; Ellis SG; Kimura T; Lip GY; Steg PG; Ten Berg JM; Manassie J; Kreuzer J; Blatchford J; Massaro JM; Brueckmann M; Ferreiros Ripoll E; Oldgren J; Hohnloser SH; Clin Cardiol; 2016 Oct; 39(10):555-564. PubMed ID: 27565018 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention. Luo L; Fu M; Li Y; Chen Z; Yu J; Luo J; Hu S; Tu L; Xu X Clin Cardiol; 2020 Mar; 43(3):235-241. PubMed ID: 31777973 [TBL] [Abstract][Full Text] [Related]
12. Ticagrelor Versus Clopidogrel in Patients with Late or Very Late Stent Thrombosis. Zhou J; Tan Y; Liu C; Zhou P; Sheng Z; Li J; Chen R; Zhao H; Song L; Yan H Cardiovasc Drugs Ther; 2020 Oct; 34(5):677-684. PubMed ID: 32572652 [TBL] [Abstract][Full Text] [Related]
13. [The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?]. Ferlini M; Galvani M; Visconti LO G Ital Cardiol (Rome); 2020 Mar; 21(3):171-174. PubMed ID: 32100728 [No Abstract] [Full Text] [Related]
14. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial. Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475 [TBL] [Abstract][Full Text] [Related]
15. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis. Wang Z; Zhou DY; Su Y; Si LY; Xu Q BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560 [TBL] [Abstract][Full Text] [Related]
16. Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009-2016. Dayoub EJ; Nathan AS; Khatana SAM; Seigerman M; Tuteja S; Kobayashi T; Kolansky DM; Groeneveld PW; Giri J Circ Cardiovasc Interv; 2019 Jan; 12(1):e007434. PubMed ID: 30608869 [No Abstract] [Full Text] [Related]